Hyloris Pharmaceuticals
@hyloris.com
Hyloris is a specialty pharma group focused on reinventing and optimizing existing medications through reformulation, repurposing and some smart NCEs developments to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals, and payors. Our development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA’s 505(b)(2) pathway in the U.S., or equivalent regulatory frameworks in other regions, which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten development timelines, leading to reduced costs and risks. We announced a broad development portfolio of 28 products, including 25 value-added medicines of which two are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high-barrier generic products approved in the U.S. and one additional high-barrier generic product in development. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. Where others stop, Hyloris starts and adds value through Reinventing Existing Medicines for unmet patient needs worldwide. Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (EBR: HYL).
Hyloris Pharmaceuticals's Company Logos
Hyloris Pharmaceuticals's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#293E6E
Astronaut
41, 62, 110
222, 46, 30
63, 44, 0, 57
#7FC9F0
Jordy Blue
127, 201, 240
201, 79, 72
47, 16, 0, 6
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
About Hyloris Pharmaceuticals
Hyloris is a leading brand that offers a wide range of products and services in the healthcare industry. With a strong focus on innovation and collaboration, they strive to provide innovative solutions to meet the evolving needs of patients and healthcare professionals. Their product portfolio includes Maxigesic® IV and Sotalol IV, which are widely recognized for their effectiveness in treating various medical conditions.
These products have generated positive outcomes and have gained immense popularity among patients and healthcare providers. Hyloris also maintains a robust pipeline of future products, constantly working on developing new and improved treatments. They have a dedicated team of experts who are committed to conducting extensive research and development to bring the best healthcare solutions to market.
Furthermore, Hyloris values transparency and good governance, ensuring they remain accountable to their investors and shareholders. They provide regular updates through press releases, financial reports, and investor presentations, keeping stakeholders well-informed about the company's progress. With a strong leadership team and a passion for making a difference in the healthcare industry, Hyloris is poised to continue its growth and success in the market.
Their commitment to innovation and patient-centric approach sets them apart as a trusted and reliable brand in the healthcare sector
Company type
Public Company
Year founded
2012
Company size
11-50 employees
Related Brands
Tags
505(b)(2) pharmaceuticals
Specialty pharma
Reformulated and repurposed medicines
Licensing and commercialization partnerships
